Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.

Doppelhammer M, Fraccaroli A, Prevalsek D, Bücklein V, Häbe S, Schulz C, Hubmann M, Hausmann A, Claus R, Rank A, Schmid C, Tischer J.

Ann Hematol. 2019 Mar;98(3):753-762. doi: 10.1007/s00277-019-03593-2. Epub 2019 Jan 8.

PMID:
30617644
2.

Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS.

Fraccaroli A, Prevalsek D, Fritsch S, Haebe S, Bücklein V, Schulz C, Hubmann M, Stemmler HJ, Ledderose G, Hausmann A, Schmid C, Tischer J.

Am J Hematol. 2018 Dec;93(12):1524-1531. doi: 10.1002/ajh.25281. Epub 2018 Oct 2.

PMID:
30194866
3.

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, Rothenberg-Thurley M, Janke H, Bräundl K, Ksienzyk B, Batcha AMN, Schaaf S, Schneider S, Bohlander SK, Görlich D, Berdel WE, Wörmann BJ, Braess J, Krebs S, Hiddemann W, Mansmann U, Spiekermann K, Greif PA.

Oncotarget. 2018 Jul 10;9(53):30128-30145. doi: 10.18632/oncotarget.25729. eCollection 2018 Jul 10.

4.

PRUNE1 Deficiency: Expanding the Clinical and Genetic Spectrum.

Alhaddad B, Schossig A, Haack TB, Kovács-Nagy R, Braunisch MC, Makowski C, Senderek J, Vill K, Müller-Felber W, Strom TM, Krabichler B, Freisinger P, Deshpande C, Polster T, Wolf NI, Desguerre I, Wörmann F, Rötig A, Ahting U, Kopajtich R, Prokisch H, Meitinger T, Feichtinger RG, Mayr JA, Jungbluth H, Hubmann M, Zschocke J, Distelmaier F, Koch J.

Neuropediatrics. 2018 Oct;49(5):330-338. doi: 10.1055/s-0038-1661396. Epub 2018 Jun 25.

PMID:
29940663
5.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

6.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. [Epub ahead of print]

PMID:
29249818
7.

CRISPR-UMI: single-cell lineage tracing of pooled CRISPR-Cas9 screens.

Michlits G, Hubmann M, Wu SH, Vainorius G, Budusan E, Zhuk S, Burkard TR, Novatchkova M, Aichinger M, Lu Y, Reece-Hoyes J, Nitsch R, Schramek D, Hoepfner D, Elling U.

Nat Methods. 2017 Dec;14(12):1191-1197. doi: 10.1038/nmeth.4466. Epub 2017 Oct 16.

PMID:
29039415
8.

A reversible haploid mouse embryonic stem cell biobank resource for functional genomics.

Elling U, Wimmer RA, Leibbrandt A, Burkard T, Michlits G, Leopoldi A, Micheler T, Abdeen D, Zhuk S, Aspalter IM, Handl C, Liebergesell J, Hubmann M, Husa AM, Kinzer M, Schuller N, Wetzel E, van de Loo N, Martinez JAZ, Estoppey D, Riedl R, Yang F, Fu B, Dechat T, Ivics Z, Agu CA, Bell O, Blaas D, Gerhardt H, Hoepfner D, Stark A, Penninger JM.

Nature. 2017 Oct 5;550(7674):114-118. doi: 10.1038/nature24027. Epub 2017 Sep 27.

9.

Modified sequential extraction for biochar and petroleum coke: Metal release potential and its environmental implications.

von Gunten K, Alam MS, Hubmann M, Ok YS, Konhauser KO, Alessi DS.

Bioresour Technol. 2017 Jul;236:106-110. doi: 10.1016/j.biortech.2017.03.162. Epub 2017 Mar 29.

PMID:
28391104
10.

Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation.

Hubmann M, Fritsch S, Zoellner AK, Prevalsek D, Engel N, Bücklein V, Mumm F, Schulz C, Stemmler HJ, Jäger G, Ledderose G, Kolb HJ, Hausmann A, Hiddemann W, Moosmann A, Tischer J.

J Clin Virol. 2016 Sep;82:33-40. doi: 10.1016/j.jcv.2016.07.002. Epub 2016 Jul 10.

PMID:
27428881
11.

The histone chaperone CAF-1 safeguards somatic cell identity.

Cheloufi S, Elling U, Hopfgartner B, Jung YL, Murn J, Ninova M, Hubmann M, Badeaux AI, Euong Ang C, Tenen D, Wesche DJ, Abazova N, Hogue M, Tasdemir N, Brumbaugh J, Rathert P, Jude J, Ferrari F, Blanco A, Fellner M, Wenzel D, Zinner M, Vidal SE, Bell O, Stadtfeld M, Chang HY, Almouzni G, Lowe SW, Rinn J, Wernig M, Aravin A, Shi Y, Park PJ, Penninger JM, Zuber J, Hochedlinger K.

Nature. 2015 Dec 10;528(7581):218-24. doi: 10.1038/nature15749.

12.

[Response].

Dietzfelbinger H, Hubmann M.

Dtsch Med Wochenschr. 2015 Nov;140(22):1647. doi: 10.1055/s-0041-107992. Epub 2015 Nov 4. German. No abstract available.

PMID:
26536633
13.

[Hemolytic anemias and vitamin B12 deficieny].

Dietzfelbinger H, Hubmann M.

Dtsch Med Wochenschr. 2015 Aug;140(17):1302-10; quiz 1311-2. doi: 10.1055/s-0041-103562. Epub 2015 Aug 25. German.

PMID:
26306021
14.

Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings.

Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, Zoellner AK, Bücklein V, Reibke R, Mumm F, Rieger CT, Hill W, Ledderose G, Stemmler HJ, Köhnke T, Jäger G, Kolb HJ, Schmid C, Moosmann A, Hausmann A.

Ann Hematol. 2015 Oct;94(10):1677-88. doi: 10.1007/s00277-015-2423-y. Epub 2015 Jun 10.

PMID:
26055139
15.

Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.

Zoellner AK, Fritsch S, Prevalsek D, Engel N, Hubmann M, Reibke R, Rieger CT, Hellmuth JC, Haas M, Mumm F, Herold T, Ledderose G, Hiddemann W, Dreyling M, Hausmann A, Tischer J.

Bone Marrow Transplant. 2015 May;50(5):679-84. doi: 10.1038/bmt.2014.328. Epub 2015 Feb 2.

PMID:
25642765
16.

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Blood. 2014 Aug 21;124(8):1304-11. doi: 10.1182/blood-2013-12-540716. Epub 2014 Jun 12.

17.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.

PMID:
24912430
18.

Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation.

Tischer J, Engel N, Fritsch S, Prevalsek D, Hubmann M, Schulz C, Zoellner AK, Bücklein V, Lippl S, Reibke R, Rieger CT, Ledderose G, Stemmler HJ, Hiddemann W, Schmid C, Hausmann A.

Bone Marrow Transplant. 2014 Jul;49(7):895-901. doi: 10.1038/bmt.2014.83. Epub 2014 May 12.

PMID:
24820212
19.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9.

20.

Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders.

Ottone T, Hasan SK, Voso MT, Ledda A, Montefusco E, Fenu S, Pagoni M, Hubmann M, Lunghi M, Platzbecker U, Lo-Coco F.

Am J Hematol. 2014 Mar;89(3):346-7. doi: 10.1002/ajh.23646. No abstract available.

21.

Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.

Tischer J, Stemmler HJ, Engel N, Hubmann M, Fritsch S, Prevalsek D, Schulz C, Zoellner AK, Bücklein V, Hill W, Ledderose G, Hausmann A.

Ann Hematol. 2013 Oct;92(10):1379-88. doi: 10.1007/s00277-013-1862-6. Epub 2013 Aug 9.

PMID:
23928857
22.

Collective opinion paper on findings of the 2011 convocation of experts on laboratory quality.

Adams O, Cooper G, Fraser C, Hubmann M, Jones G, Plebani M, Sonntag O, Vaubourdolle M.

Clin Chem Lab Med. 2012;50(9):1547-58. doi: 10.1515/cclm-2012-0003.

PMID:
23092802
23.

Selection of deep brain stimulation candidates in private neurology practices: referral may be simpler than a computerized triage system.

Oyama G, Rodriguez RL, Jones JD, Swartz C, Merritt S, Unger R, Hubmann M, Delgado A, Simon E, Doniger GM, Bowers D, Foote KD, Fernandez HH, Okun MS.

Neuromodulation. 2012 May-Jun;15(3):246-50; discussion 250. doi: 10.1111/j.1525-1403.2012.00437.x. Epub 2012 Feb 29.

PMID:
22376158
24.

Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia.

Ottone T, Cicconi L, Hasan SK, Lavorgna S, Divona M, Voso MT, Montefusco E, Melillo L, Barragán E, Platzbecker U, Giannì L, Hubmann M, Pagoni M, Amadori S, Lo-Coco F.

Leuk Res. 2012 Apr;36(4):474-8. doi: 10.1016/j.leukres.2011.10.015. Epub 2011 Nov 8.

PMID:
22071137
25.

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.

Ammatuna E, Montesinos P, Hasan SK, Ramadan SM, Esteve J, Hubmann M, Pagoni M, Grimwade D, Sanz MA, Lo-Coco F.

Haematologica. 2011 Apr;96(4):621-5. doi: 10.3324/haematol.2010.036657. Epub 2010 Dec 29.

26.

[Swollen lymph node: infectious disease or malignancy].

Dietzfelbinger H, Hubmann M.

MMW Fortschr Med. 2010 Sep 9;152(36):27-8. German. No abstract available.

PMID:
21192461
27.

Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D.

Leukemia. 2011 Mar;25(3):498-505. doi: 10.1038/leu.2010.283. Epub 2010 Dec 7.

PMID:
21135860
28.

[Hepcidin--newly-discovered regulator of iron metabolism].

Von Dietzfelbinger H, Abbrederis K, Hubmann M.

MMW Fortschr Med. 2010 Apr 8;152 Suppl 1:7-11. Review. German. No abstract available.

PMID:
20942301
29.

The relevance of oxidative stress and cytotoxic DNA lesions for spontaneous mutagenesis in non-replicating yeast cells.

Steinboeck F, Hubmann M, Bogusch A, Dorninger P, Lengheimer T, Heidenreich E.

Mutat Res. 2010 Jun 1;688(1-2):47-52. doi: 10.1016/j.mrfmmm.2010.03.006. Epub 2010 Mar 17.

PMID:
20223252
30.

Influence of cementless femoral stems inserted in varus on functional outcome in primary total hip arthroplasty.

de Beer J, McKenzie S, Hubmann M, Petruccelli D, Winemaker M.

Can J Surg. 2006 Dec;49(6):407-11.

31.

Total homocysteine, folate, and cobalamin, and their relation to genetic polymorphisms, lifestyle and body mass index in healthy children and adolescents.

Huemer M, Vonblon K, Födinger M, Krumpholz R, Hubmann M, Ulmer H, Simma B.

Pediatr Res. 2006 Dec;60(6):764-9. Epub 2006 Oct 25.

PMID:
17065574
32.

Incidence and timing of myocardial infarction after total joint arthroplasty.

Gandhi R, Petruccelli D, Devereaux PJ, Adili A, Hubmann M, de Beer J.

J Arthroplasty. 2006 Sep;21(6):874-7.

PMID:
16950042
33.

The effects of loading and unloading treadmill walking on balance, gait, fall risk, and daily function in Parkinsonism.

Toole T, Maitland CG, Warren E, Hubmann MF, Panton L.

NeuroRehabilitation. 2005;20(4):307-22.

PMID:
16403997
34.

Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation.

Huemer M, Ausserer B, Graninger G, Hubmann M, Huemer C, Schlachter K, Tscharre A, Ulmer H, Simma B.

Epilepsia. 2005 Oct;46(10):1677-83.

35.

Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone.

Höfle G, Holzmüller H, Gouya G, Hergan K, Hubmann M, Langer P, Drexel H.

Transpl Int. 2003 Jul;16(7):523-8. Epub 2003 Apr 4.

PMID:
12677365
36.

Cardiovascular function of workers exposed to carbon disulphide.

Korinth G, Göen T, Ulm K, Hardt R, Hubmann M, Drexler H.

Int Arch Occup Environ Health. 2003 Feb;76(1):81-5. Epub 2002 Oct 12.

PMID:
12592587
37.
38.

Lack of association between childhood stroke after varicella and human leukocyte antigen (HLA)-B51.

Kluger G, Hubmann M, Vogler L, Berz K.

Eur J Paediatr Neurol. 2001;5(6):259-60.

PMID:
11764184
39.

[Practical usage of a quality management system according to ISO 9001 : 2000 focusing on the double contrast (barium) enema].

Heinzle G, Hergan K, Fleisch M, Hubmann M, Oser W.

Rofo. 2001 Dec;173(12):1118-25. German.

PMID:
11740673
40.

Comparison between three transmucosal routes of administration of midazolam in children.

Geldner G, Hubmann M, Knoll R, Jacobi K.

Paediatr Anaesth. 1997;7(2):103-9.

PMID:
9188109
41.

Carbon disulphide. IV. Cardiovascular function in workers in the viscose industry.

Drexler H, Ulm K, Hardt R, Hubmann M, Göen T, Lang E, Angerer J, Lehnert G.

Int Arch Occup Environ Health. 1996;69(1):27-32.

PMID:
9017431
42.

[Analysis of myocardial evoked potentials in relation to ergometric load and heart rate for use in frequency-adaptive cardiac pacemakers].

Wetzig T, Fischer G, Worth H, Hardt R, Hubmann M, Bolz A, Schaldach M.

Biomed Tech (Berl). 1995 Jan-Feb;40(1-2):9-13. German.

PMID:
7703348
43.

Carbon disulphide. III. Risk factors for coronary heart diseases in workers in the viscose industry.

Drexler H, Ulm K, Hubmann M, Hardt R, Göen T, Mondorf W, Lang E, Angerer J, Lehnert G.

Int Arch Occup Environ Health. 1995;67(4):243-52.

PMID:
7591185
45.

Low polarization pacing lead for detecting the ventricular-evoked response.

Bolz A, Hubmann M, Hardt R, Riedmüller J, Schaldach M.

Med Prog Technol. 1993;19(3):129-37.

PMID:
8127278
46.

Nonimmunological assay of urinary albumin based on laser-induced fluorescence.

Kessler MA, Hubmann MR, Dremel BA, Wolfbeis OS.

Clin Chem. 1992 Oct;38(10):2089-92.

47.

Sputter-deposited TiN electrode coatings for superior sensing and pacing performance.

Schaldach M, Hubmann M, Weikl A, Hardt R.

Pacing Clin Electrophysiol. 1990 Dec;13(12 Pt 2):1891-5.

PMID:
1704562
49.

[Long-term stability of the detection and threshold behavior of titanium nitride pacemaker electrodes].

Bolz A, Matlok H, Still M, Schaldach M, Hubmann M, Hardt R.

Biomed Tech (Berl). 1990;35 Suppl 3:131-3. German. No abstract available.

PMID:
2078665
50.

[Motion energy as a control variable for adapting stimulation frequency].

Hubmann M, Weikl A, Hardt R, Schaldach M.

Biomed Tech (Berl). 1989 Jul-Aug;34(7-8):191-6. German.

PMID:
2775826

Supplemental Content

Loading ...
Support Center